Prior disclosure of corresponding protein sequences or uncharacterized DNA sequences may impact your chances to patent a newly discovered DNA.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Amgen Inc. v. Chugai Pharmaceutical Co., Ltd., 9 USPQ2d 1833 (D. Mass. 1989); 18 USPQ2d 1016 (Fed. Cir. 1991).
In re Bell 26 USPQ2d 1529 (Fed. Cir. 1993).
In re Deuel 34 USPQ2d 1210 (Fed. Cir. 1995).
In re Deuel, 34 USPQ2d at 1215.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Agris, C. Prior art considerations when patenting DNA sequences. Nat Biotechnol 14, 1309–1310 (1996). https://doi.org/10.1038/nbt1096-1309
Issue Date:
DOI: https://doi.org/10.1038/nbt1096-1309
This article is cited by
-
Patenting DNA sequences
Nature Biotechnology (1998)